# Farnesol, a Dietary Sesquiterpene, Attenuates Rotenone-Induced Dopaminergic Neurodegeneration by Inhibiting Oxidative Stress, Inflammation, and Apoptosis via Mediation of Cell Signaling Pathways in Rats

**Authors:** Lujain Bader Eddin, Seenipandi Arunachalam, Sheikh Azimullah, Mohamed Fizur Nagoor Meeran, Mouza Ali Hasan AlQaishi Alshehhi, Amar Mahgoub, Rami Beiram, Shreesh Ojha

PMC · DOI: 10.3390/ijms27020811 · 2026-01-14

## TL;DR

Farnesol, a natural compound, protects against Parkinson's disease by reducing brain inflammation, oxidative stress, and cell death in rats exposed to a toxin.

## Contribution

Farnesol's protective effects against dopaminergic neurodegeneration are demonstrated through multiple cellular mechanisms in a rat model of Parkinson's disease.

## Key findings

- Farnesol reduced inflammation by suppressing TLR4, NF-κB, and related inflammatory markers.
- Farnesol enhanced antioxidant activity by increasing SOD and catalase while lowering oxidative stress markers.
- Farnesol restored autophagy and preserved BDNF and tyrosine hydroxylase levels in the brain.

## Abstract

Parkinson’s disease is a neurodegenerative disorder that affects the elderly population worldwide. Rotenone (ROT) is an environmental toxin that impairs mitochondrial dynamics by inhibiting respiratory chain complex I and thus inducing oxidative stress. Farnesol (FSL) is a dietary sesquiterpene with antioxidant and anti-inflammatory properties reported in various in vivo models. To evaluate the efficacy of FSL in the management of PD, Wistar rats were injected with ROT (2.5 mg/kg, i.p) and pretreated with FSL. Immunohistochemical staining measured tyrosine hydroxylase-positive cells in the substantia nigra and striatum. Western blotting was employed to determine protein expression of inflammatory, apoptotic, and autophagic markers. Our results indicate that FSL significantly protected against ROT-induced inflammation by suppressing microglial and astrocytic activation through the downregulation of Toll-Like receptor 4 (TLR4), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), inhibitor of kappa B (IkB), inducible nitric oxide synthase (iNOS), cyclooxygenase (COX), matrix metalloproteinase-9 (MMP-9) expression. FSL has also demonstrated an antioxidant effect by enhancing the activity of superoxide dismutase and catalase while reducing the level of Malondialdehyde and nitric oxide. Moreover, it restored homeostasis in ROT-induced imbalance between pro- and anti-apoptotic proteins. Impaired autophagy observed in ROT-injected rats was corrected by FSL treatment, which upregulated phosphorylated mammalian target of rapamycin (p-mTOR) expression and downregulated P62, an autophagosome marker. The protective effect of FSL was further supported by preserving the brain-derived neurotrophic factor (BDNF) and tyrosine hydroxylase in the brain. These findings demonstrate the neuroprotective ability of FSL and its potential to be developed as a pharmaceutical or nutraceutical agent for the prevention and treatment of PD by mitigating neuropathological changes observed in dopaminergic neurodegeneration.

## Linked entities

- **Genes:** TLR4 (toll like receptor 4) [NCBI Gene 7099], NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790], Nfkbib (nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, beta) [NCBI Gene 18036], NOS2 (nitric oxide synthase 2) [NCBI Gene 4843], COX8A (cytochrome c oxidase subunit 8A) [NCBI Gene 1351], MMP9 (matrix metallopeptidase 9) [NCBI Gene 4318], GTF2H1 (general transcription factor IIH subunit 1) [NCBI Gene 2965], BDNF (brain derived neurotrophic factor) [NCBI Gene 627]
- **Proteins:** TLR4 (toll like receptor 4), NFKB1 (nuclear factor kappa B subunit 1), Nfkbib (nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, beta), NOS2 (nitric oxide synthase 2), COX8A (cytochrome c oxidase subunit 8A), MMP9 (matrix metallopeptidase 9), GTF2H1 (general transcription factor IIH subunit 1), BDNF (brain derived neurotrophic factor), SOD1 (superoxide dismutase 1), Cat (Catalase)
- **Chemicals:** farnesol (PubChem CID 445070), rotenone (PubChem CID 6758)
- **Diseases:** Parkinson’s disease (MONDO:0005180)
- **Species:** Rattus norvegicus (taxon 10116)

## Full-text entities

- **Genes:** Th (tyrosine hydroxylase) [NCBI Gene 25085] {aka The}, Cat (catalase) [NCBI Gene 24248] {aka CS1, Cas1, Cat01, Catl, Cs-1}, Khdrbs1 (KH RNA binding domain containing, signal transduction associated 1) [NCBI Gene 117268] {aka P62, Sam68}, Mmp9 (matrix metallopeptidase 9) [NCBI Gene 81687], Nos2 (nitric oxide synthase 2) [NCBI Gene 24599] {aka Nos2a, iNos}, Bdnf (brain-derived neurotrophic factor) [NCBI Gene 24225], Mtor (mechanistic target of rapamycin kinase) [NCBI Gene 56718] {aka Frap1, RAFT1}, Tlr4 (toll-like receptor 4) [NCBI Gene 29260]
- **Diseases:** Inflammation (MESH:D007249), PD (MESH:D010300), Neurodegeneration (MESH:D019636)
- **Chemicals:** ROT (MESH:D012402), Malondialdehyde (MESH:D008315), Sesquiterpene (MESH:D012717), FSL (MESH:D005204), nitric oxide (MESH:D009569)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116]

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12841085/full.md

---
Source: https://tomesphere.com/paper/PMC12841085